Loading clinical trials...
Loading clinical trials...
A Multi-Center, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Olutasidenib on the Pharmacokinetics of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Substrates in Patients With IDH1 Mutation-Positive Malignancies Being Treated With Olutasidenib
Conditions
Interventions
Olutasidenib
CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates
Locations
2
United States
UCI Irvine Health
Orange, California, United States
New York Presbyterian Hospital-Columbia University Medical Center
New York, New York, United States
Start Date
February 23, 2026
Primary Completion Date
April 30, 2027
Completion Date
June 30, 2027
Last Updated
March 20, 2026
NCT03206060
NCT07243470
NCT05099003
NCT05969860
NCT03340506
NCT06503146
Lead Sponsor
Rigel Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions